Japanese clinicians report their real-life experience of administering new anti-complementary molecules in a series of 36 adults with a refractory form of myasthenia gravis (3% of a total cohort of 1,106 myasthenic patients):
- the 36 patients concerned had received eculizumab (Soliris®) as first-line treatment for an average of 35 months,
- clinical benefit was observed in 70% of cases,
- of those who switched to ravulizumab (Ultomiris®), 6 showed only a partial response,
- age at onset of myasthenia was a predictive factor for good response to treatment,
- when surveyed by questionnaire, patients expressed a preference for ravulizumab.
Such real-life studies are always instructive and, in this case, confirm the therapeutic value of these new-generation drugs.
